Annual report pursuant to Section 13 and 15(d)

Collaboration Arrangements - Additional Information (Detail)

v3.3.1.900
Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($)
$ in Millions
12 Months Ended 47 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2015
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Upfront and milestone payments received to date $ 110.0       $ 110.0
Collaboration payments achieved and received     $ 42.5 $ 67.5  
Revenue recognized by the Company 76.9 $ 14.7 12.5    
Company received a reimbursement for eligible worldwide development expenses $ 11.6 $ 21.9 $ 16.5    
Collaborative Arrangement Product Agreement | Evofosfamide          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Merck KGaA's percentage share of worldwide development expenses 70.00%